Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma
- PMID: 34801560
- DOI: 10.1016/j.yexcr.2021.112910
Incomplete radiofrequency ablation induced chemoresistance by up-regulating heat shock protein 70 in hepatocellular carcinoma
Abstract
Radiofrequency ablation (RFA) is a common minimally invasive treatment for hepatocellular carcinoma (HCC). Incomplete RFA (iRFA) due to the sub-lethal heat shock challenge of some cell populations leads to the generation of transformed survivor cells with enhanced chemoresistance. However, the underlying mechanism of iRFA on HCCs chemoresistance remains unknown. In the present study, we investigated the effect of iRFA on HCCs sensitivity to cisplatin. Cells treated with the sub-lethal heat shock challenge were used to mimic iRFA treatment in vitro. An orthotopic implantation HCC model was established and also performed iRFA treatment. Flow cytometry, transwell assay, and cell counting kit-8 assay were used to determine the effect of iRFA treatment on cisplatin-induced HCC cell apoptosis, invasion, and cell viability. ELISA and Western blot were used to detect the effect of iRFA treatment on cisplatin-induced HCC cell pyroptosis. We found that iRFA treatment increased the HCC cell proliferation and invasion ability, and inhibited cisplatin-induced pyroptosis. Further experiments showed that iRFA treatment induced upregulation of HSP70, which inhibited the cisplatin-induced NLRP3 inflammasome activation, leading to inhibition of pyroptosis. HSP70 knockdown or NLRP3 overexpression could reverse the effect of iRFA treatment in vitro. In vivo, HSP70 knockdown reversed the chemosensitivity of HCC to cisplatin, which was decreased by iRFA. In conclusion, we demonstrated that iRFA induced drug resistance by HSP70-mediated inhibition of cell pyroptosis in HCC.
Keywords: Cell pyroptosis; Chemoresistance; Heat shock protein 70; Hepatocellular carcinoma; Incomplete radiofrequency ablation.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
-
Insufficient radiofrequency ablation promotes proliferation of residual hepatocellular carcinoma via autophagy.Cancer Lett. 2018 May 1;421:73-81. doi: 10.1016/j.canlet.2018.02.024. Epub 2018 Feb 16. Cancer Lett. 2018. PMID: 29458142
-
A novel role of AIM2 inflammasome-mediated pyroptosis in radiofrequency ablation of hepatocellular carcinoma.Ann Hepatol. 2024 Nov-Dec;29(6):101532. doi: 10.1016/j.aohep.2024.101532. Epub 2024 Jul 22. Ann Hepatol. 2024. PMID: 39048057
-
The HSP90 inhibitor, XL888, enhanced cell apoptosis via downregulating STAT3 after insufficient radiofrequency ablation in hepatocellular carcinoma.Life Sci. 2021 Oct 1;282:119762. doi: 10.1016/j.lfs.2021.119762. Epub 2021 Jun 26. Life Sci. 2021. PMID: 34186047
-
An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation.J Hepatocell Carcinoma. 2022 Apr 26;9:343-355. doi: 10.2147/JHC.S358539. eCollection 2022. J Hepatocell Carcinoma. 2022. PMID: 35502292 Free PMC article. Review.
-
Burning down the house: Pyroptosis in the tumor microenvironment of hepatocellular carcinoma.Life Sci. 2024 Jun 15;347:122627. doi: 10.1016/j.lfs.2024.122627. Epub 2024 Apr 16. Life Sci. 2024. PMID: 38614301 Review.
Cited by
-
Synergistically Augmenting Cancer Immunotherapy by Physical Manipulation of Pyroptosis Induction.Phenomics. 2024 Jun 22;4(3):298-312. doi: 10.1007/s43657-023-00140-y. eCollection 2024 Jun. Phenomics. 2024. PMID: 39398428 Free PMC article. Review.
-
Extracellular Vesicles and the Inflammasome: An Intricate Network Sustaining Chemoresistance.Front Oncol. 2022 Apr 22;12:888135. doi: 10.3389/fonc.2022.888135. eCollection 2022. Front Oncol. 2022. PMID: 35530309 Free PMC article. Review.
-
Animal Models of Hepatocellular Carcinoma for Local-Regional Intraarterial Therapies.Radiol Imaging Cancer. 2022 Jul;4(4):e210098. doi: 10.1148/rycan.210098. Radiol Imaging Cancer. 2022. PMID: 35838531 Free PMC article. Review.
-
Targeting Heat Shock Proteins in Malignant Brain Tumors: From Basic Research to Clinical Trials.Cancers (Basel). 2022 Nov 4;14(21):5435. doi: 10.3390/cancers14215435. Cancers (Basel). 2022. PMID: 36358853 Free PMC article. Review.
-
Study of the Fe3O4@ZIF-8@Sor Composite Modified by Tannic Acid for the Treatment of Sorafenib-Resistant Hepatocellular Carcinoma.ACS Omega. 2023 Sep 12;8(42):39174-39185. doi: 10.1021/acsomega.3c04215. eCollection 2023 Oct 24. ACS Omega. 2023. PMID: 37901534 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical